Asymptomatic MGD more common than symptomatic

Article

A symptom-based approach may lead to an underestimation of MGD prevalence

"The high proportion of asymptomatic patients should alert us to the possibility of unnoticed progression of meibomian gland dysfunction (MGD)," emphasized Dr Eloy Viso (Servico de Oftalmología, Complexo Hospitalario de Pontevedra, Pontevedra, Spain) when discussing the results of a recent study on a general Spanish adult population.

The study

A population-based approach was used to obtain a representative sample of the population noted Dr Viso. The possibility of selection bias was also evaluated to ensure the results were fair. "We used a stratified sampling procedure so a representative sample could be obtained in each age group and we performed a design based analysis to account for the stratified sampling and the unequal probability selection," added Dr Viso. "With respect to diagnostic criteria, which are an important cause of variability between studies, we included signs of the 2 categories described in the new MGD classification to reduce the number of false negatives and removed indirect indicators to reduce the number of false positives."

Additionally, a standardized symptoms questionnaire was employed. "We used the questionnaire developed by Schein et al.1 because it was the most widely used in population-based studies and because it included symptoms such as eyes stuck shut that have been considered, in spite of a lack of sufficient evidence, more characteristic of MGD," he continued. "The biomicroscopic examination of the ocular surface, however, was performed without knowledge of the results of the questionnaire."

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.